Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 12:00 ET | Source: Kailera Therapeutics, Inc.; Hengrui Pharma

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week
November 03, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors
October 21, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.
October 14, 2025 06:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

Kailera Therapeutics announced a $600M Series B financing led by new investor Bain Capital Private Equity to support its late-stage obesity portfolio.
August 27, 2025 08:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Participate in Upcoming Investor Conferences

Kailera Therapeutics announced participation in upcoming investor conferences.
July 15, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.
June 16, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

Hengrui Pharma and Kailera today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA).
June 05, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors

Kailera Therapeutics today announced the appointments of Adam Koppel and Christopher Hite to its Board of Directors.
January 27, 2025 07:45 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.
January 13, 2025 08:00 ET | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.